Is there a role for microbiome-based approach in common variable immunodeficiency?
© 2023. The Author(s)..
Common variable immunodeficiency (CVID) is a primary immunodeficiency characterized by low levels of serum immunoglobulins and increased susceptibility to infections, autoimmune disorders and cancer. CVID embraces a plethora of heterogeneous manifestations linked to complex immune dysregulation. While CVID is thought to be due to genetic defects, the exact cause of this immune disorder is unknown in the large majority of cases. Compelling evidences support a linkage between the gut microbiome and the CVID pathogenesis, therefore a potential for microbiome-based treatments to be a therapeutic pathway for this disorder. Here we discuss the potential of treating CVID patients by developing a gut microbiome-based personalized approach, including diet, prebiotics, probiotics, postbiotics and fecal microbiota transplantation. We also highlight the need for a better understanding of microbiota-host interactions in CVID patients to prime the development of improved preventive strategies and specific therapeutic targets.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Clinical and experimental medicine - 23(2023), 6 vom: 03. Okt., Seite 1981-1998 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Poto, Remo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Common variable immunodeficiency |
|---|
| Anmerkungen: |
Date Completed 02.10.2023 Date Revised 04.10.2023 published: Print-Electronic ErratumIn: Clin Exp Med. 2023 Mar 14;:. - PMID 36917415 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10238-023-01006-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352475102 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352475102 | ||
| 003 | DE-627 | ||
| 005 | 20231226053817.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10238-023-01006-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1174.xml |
| 035 | |a (DE-627)NLM352475102 | ||
| 035 | |a (NLM)36737487 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Poto, Remo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Is there a role for microbiome-based approach in common variable immunodeficiency? |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.10.2023 | ||
| 500 | |a Date Revised 04.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Clin Exp Med. 2023 Mar 14;:. - PMID 36917415 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Common variable immunodeficiency (CVID) is a primary immunodeficiency characterized by low levels of serum immunoglobulins and increased susceptibility to infections, autoimmune disorders and cancer. CVID embraces a plethora of heterogeneous manifestations linked to complex immune dysregulation. While CVID is thought to be due to genetic defects, the exact cause of this immune disorder is unknown in the large majority of cases. Compelling evidences support a linkage between the gut microbiome and the CVID pathogenesis, therefore a potential for microbiome-based treatments to be a therapeutic pathway for this disorder. Here we discuss the potential of treating CVID patients by developing a gut microbiome-based personalized approach, including diet, prebiotics, probiotics, postbiotics and fecal microbiota transplantation. We also highlight the need for a better understanding of microbiota-host interactions in CVID patients to prime the development of improved preventive strategies and specific therapeutic targets | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Common variable immunodeficiency | |
| 650 | 4 | |a Fecal microbiota transplantation | |
| 650 | 4 | |a Gut microbiome | |
| 650 | 4 | |a Microbiome-based therapies | |
| 650 | 4 | |a Personalized medicine | |
| 700 | 1 | |a Laniro, Gianluca |e verfasserin |4 aut | |
| 700 | 1 | |a de Paulis, Amato |e verfasserin |4 aut | |
| 700 | 1 | |a Spadaro, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Marone, Gianni |e verfasserin |4 aut | |
| 700 | 1 | |a Gasbarrini, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Varricchi, Gilda |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental medicine |d 2001 |g 23(2023), 6 vom: 03. Okt., Seite 1981-1998 |w (DE-627)NLM113691408 |x 1591-9528 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:6 |g day:03 |g month:10 |g pages:1981-1998 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10238-023-01006-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 6 |b 03 |c 10 |h 1981-1998 | ||